skip to content

Contract Wins and Joint Ventures

PureTech Health subsidiary in asthma, allergy JV

05 May 2017 09:17

PureTech Health has announced a licensing agreement between subsidiary Commense Inc and the University of British Columbia (UBC) for a microbiome-based therapy directed toward the prevention of asthma and other allergic diseases that present in childhood.

This live biotherapeutic product bolsters Commense's pipeline of novel therapeutic programs designed to nurture a healthy microbiome early in life.

At 9:17am: (LON:PRTC) PureTech Health Plc share price was +3.13p at 115.13p

Story provided by

Related Company: PRTC

Info Point:

To buy or sell shares call our Dealing Room on 0113 243 6941.

Too much jargon? Our glossary will help make sense of things.

Find out more about our Share Dealing Services.

Client Area Access

» Secure Login

» Not registered yet?


Branch Finder

Redmayne-Bentley have High Street branches throughout the UK. Find your nearest branch.